World Stroke Day: Evaluation of Animal Drug Efficacy Models for the Development of Cardiovascular and Cerebrovascular Drugs

Animal Drug Efficacy Models for the Development of Cardiovascular and Cerebrovascular Drugs

October 29, 2022

October 29th, 2022, is the seventeenth “World Stroke Day.” “World Stroke Day” was established by the World Stroke Organization (World Stroke Organization) to call for strengthening public awareness of stroke globally.

Stroke is the scientific name of cerebralvascular accident, which generally refers to ischemic or hemorrhagic diseases of the heart, brain and tissues of the whole province caused by hyperlipidemia, blood clotting, atherosclerosis, hypertension, etc. It is a sudden onset of cerebral blood circulation disorders. The clinical manifestations are mainly characterized by sudden dizziness, unconsciousness, or sudden deviated eyes, hemiplegia, and intellectual disability. Stroke mainly includes ischemic stroke (transient ischemic attack, atherosclerotic thrombotic cerebral infarction, lacunar cerebral infarction, cerebral embolism) and hemorrhagic stroke (cerebral hemorrhage, subarachnoid hemorrhage).

Stroke is known as “the number one killer of human health” because of its high prevalence, high morbidity, high mortality and high disability rate. In China, the annual treatment cost of cardiovascular and cerebrovascular diseases is 540.6 billion yuan. The annual treatment cost of cerebrovascular diseases accounts for 25.68% of cardiovascular and cerebrovascular diseases. Among them, ischemic stroke accounts for 18% and hemorrhagic stroke accounts for 7%.

Although the annual treatment cost of stroke is so high, there is still a problem that there are few drugs for clinical specific treatment, and there is a huge gap in the demand for clinical drugs. Therefore, the market potential of stroke drugs is great and the development prospect is good.

For the preclinical development of stroke drugs, the two mountains of pharmacokinetics and pharmacodynamics cannot be avoided, and the models used in both pharmacokinetics and pharmacodynamics are particularly important.

Medicilon's Rodent Cerebrovascular Disease Drug Efficacy Evaluation System

Model evaluation is a critical step in testing results. Medicilon strictly follows the STAIR preclinical drug development strategy for stroke, and has rich experience in MCAO model establishment and a mature MCAO model system evaluation system.

Click Here

Summary and Outlook

In recent years, with the continuous development of biomedical technology, more and more stroke drugs have gone from the target to the stage of preclinical testing. We believe the problem will be solved soon！

此博客中的热门博文

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客